Heading
Beamion LUNG-1, an ongoing Phase Ia/Ib trial of the HER2 TKI, zongertinib (BI 1810631) in patients (pts) with advanced solid tumours with HER2 aberrations: latest data
Author(s): Ruiter et al.
Tumor type(s): Solid tumors
Compound/Target: HER2 TKI
Format
Type
CTA
Congress
Card Order
84
Year